Is LQDA a Buy? What to Consider in 2026
Last updated July 2026
Short answer
The bull case for Liquidia Corporation (LQDA) rests on Yutrepia commercial ramp: Yutrepia posted about $130 million in first-quarter 2026 net sales, up sharply sequentially, and the company reported more than 4,500 unique prescriptions and roughly 3,750 patients treated since the June 2025 launch. Q1 2026 revenue is ~$133M (Yutrepia net sales ~$130M). If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: Liquidia is highly concentrated: the vast majority of revenue comes from a single drug, Yutrepia, in a single therapeutic area, so any slowdown in uptake, reimbursement pressure, or manufacturing or supply issue would hit results disproportionately. Whether LQDA is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Liquidia Corporation is a specialty pharmaceutical company focused on treating pulmonary hypertension. Its lead product, Yutrepia (treprostinil inhalation powder), is a dry-powder inhaled prostacyclin approved for pulmonary arterial hypertension (PAH) and for pulmonary hypertension associated with interstitial lung disease (PH-ILD). Yutrepia received final FDA approval in May 2025 and launched commercially in June 2025. The company also runs a legacy generic-treprostinil business (Yuvanci/Treprostinil Injection) and is developing L606, an investigational sustained-release inhaled treprostinil dosed twice daily with a next-generation nebulizer, now in the pivotal Phase 3 Re-Spire study. The investment picture centers on a fast single-product ramp turning into durable profitability. Yutrepia generated roughly $130 million of net sales in the first quarter of 2026, the company's third consecutive profitable quarter, and management has cited an annualized run rate above $0.5 billion within its first year on the market plus a stated line of sight to at least $1 billion in net revenue by 2027. The counterweights are a premium valuation (a market cap near $7 billion on a company still early in its commercial life), heavy concentration in one drug and one disease area, and unresolved patent litigation brought by United Therapeutics, whose Tyvaso franchise Yutrepia competes against directly.
What's the case for buying LQDA?
1. Yutrepia commercial ramp
Yutrepia posted about $130 million in first-quarter 2026 net sales, up sharply sequentially, and the company reported more than 4,500 unique prescriptions and roughly 3,750 patients treated since the June 2025 launch. Management has pointed to a conversion rate at or above 85%, suggesting strong onboarding and retention. Continued share gains in inhaled prostacyclins are the main driver of the story.
2. Swing to profitability
The rapid revenue ramp pushed Liquidia to net income of roughly $53 million and adjusted EBITDA near $71 million in the first quarter of 2026, its third straight profitable quarter. Cash and equivalents stood around $223 million at quarter end, up from the prior period. A profitable, cash-generative base changes the risk profile versus a typical pre-revenue biotech.
3. Expanding indications and label reach
Yutrepia is approved for both PAH and PH-ILD, and Liquidia is screening patients for a Phase 4 study evaluating transition of patients from Tyvaso and Tyvaso DPI to Yutrepia in PH-ILD. Broadening the treated population and reinforcing switch data are levers to grow the addressable market beyond current prescribers.
4. L606 and pipeline optionality
L606, a sustained-release inhaled treprostinil prodrug dosed twice daily, is in the pivotal Phase 3 Re-Spire study and represents the next potential product beyond Yutrepia. Success would extend the franchise and reduce single-product dependence, though marketing approval is not assured and any launch is years away.
What are the risks to LQDA?
Liquidia is highly concentrated: the vast majority of revenue comes from a single drug, Yutrepia, in a single therapeutic area, so any slowdown in uptake, reimbursement pressure, or manufacturing or supply issue would hit results disproportionately. United Therapeutics has an ongoing patent-infringement lawsuit (centered on U.S. Patent No. 11,826,327, which expires in 2042) that went to trial in June 2025 with a decision awaited, and an adverse ruling in that or related patent matters could limit Liquidia's ability to keep approval for or commercialize Yutrepia. The company competes directly against United Therapeutics' larger, entrenched Tyvaso franchise. The stock also carries a premium valuation that assumes continued rapid growth toward the stated $1 billion 2027 target, so any disappointment on volumes, pricing, or litigation could produce sharp downside, and L606 approval is not guaranteed.
How is LQDA valued? (as of JULY 2026)
Snapshot for LQDA as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Q1 2026 revenue: ~$133M (Yutrepia net sales ~$130M)
- Revenue (TTM): ~$300M (Yutrepia launched June 2025)
- Q1 2026 net income: ~$53M (third straight profitable quarter)
- Q1 2026 adjusted EBITDA: ~$71M
- Cash and equivalents: ~$223M (Mar 31, 2026)
- Market cap: ~$7B
Liquidia trades at a large multiple of its trailing revenue, reflecting how much of the story is future Yutrepia growth toward the company's stated $1 billion 2027 revenue target rather than results already booked. The shares traded in roughly the low-to-high $70s in early-to-mid July 2026, well above levels from before the launch. Because revenue is concentrated in one product still early in its ramp, the valuation is sensitive to quarterly uptake data and to the outcome of the United Therapeutics patent litigation.
How do you decide if LQDA is a buy?
Rather than asking whether LQDA is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold LQDA indirectly through an index or sector ETF before adding more.
For the full picture, see the LQDA stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about LQDA against your real portfolio and see your actual exposure before deciding.
The bottom line on LQDA
The bottom line: Liquidia Corporation's story right now is Yutrepia commercial ramp, with q1 2026 revenue at ~$133M (Yutrepia net sales ~$130M). If you believe that narrative continues, the call is about sizing LQDA sensibly and checking overlap with what you own; if you doubt it (the risk: liquidia is highly concentrated: the vast majority of revenue comes from a single drug, Yutrepia, in a single therapeutic area, so any slowdown in uptake, reimbursement pressure, or manufacturing or supply issue would hit results disproportionately.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around LQDA with Walnut
Use Liquidia Corporation as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is LQDA a good stock to buy right now?
+
The case for Liquidia Corporation right now is Yutrepia commercial ramp, with q1 2026 revenue at ~$133M (Yutrepia net sales ~$130M). If you believe that thesis holds, LQDA is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is liquidia is highly concentrated: the vast majority of revenue comes from a single drug, Yutrepia, in a single therapeutic area, so any slowdown in uptake, reimbursement pressure, or manufacturing or supply issue would hit results disproportionately. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Liquidia Corporation do?
+
Liquidia Corporation is a specialty pharmaceutical company focused on treating pulmonary hypertension.
What are the main risks of LQDA?
+
Liquidia is highly concentrated: the vast majority of revenue comes from a single drug, Yutrepia, in a single therapeutic area, so any slowdown in uptake, reimbursement pressure, or manufacturing or supply issue would hit results disproportionately. United Therapeutics has an ongoing patent-infringement lawsuit (centered on U.S. Patent No. 11,826,327, which expires in 2042) that went to trial in June 2025 with a decision awaited, and an adverse ruling in that or related patent matters could limit Liquidia's ability to keep approval for or commercialize Yutrepia. The company competes directly against United Therapeutics' larger, entrenched Tyvaso franchise. The stock also carries a premium valuation that assumes continued rapid growth toward the stated $1 billion 2027 target, so any disappointment on volumes, pricing, or litigation could produce sharp downside, and L606 approval is not guaranteed.
What does Liquidia Corporation do?
+
Liquidia is a specialty pharmaceutical company focused on pulmonary hypertension. Its lead product, Yutrepia, is an inhaled dry-powder form of treprostinil approved for pulmonary arterial hypertension and PH-ILD, and it is also developing L606, a longer-acting inhaled treprostinil candidate.
Is LQDA profitable?
+
Yes, recently. Driven by Yutrepia's rapid launch, Liquidia reported net income of roughly $53 million and adjusted EBITDA near $71 million in the first quarter of 2026, its third consecutive profitable quarter, a notable shift for a company that was pre-revenue before the June 2025 launch.
What is Yutrepia?
+
Yutrepia is Liquidia's inhaled dry-powder treprostinil product for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. It received final FDA approval in May 2025, launched in June 2025, and generated about $130 million in net sales in the first quarter of 2026.
How fast is Yutrepia growing?
+
Very fast off a small base. Liquidia reported more than 4,500 unique prescriptions and roughly 3,750 patients treated since launch, with sales rising sharply each quarter and an annualized run rate the company says exceeded $0.5 billion within the first year on the market.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell LQDA; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.